Compare ENB & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENB | BSX |
|---|---|---|
| Founded | 1949 | 1979 |
| Country | Canada | United States |
| Employees | 14800 | N/A |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.5B | 103.6B |
| IPO Year | N/A | 2010 |
| Metric | ENB | BSX |
|---|---|---|
| Price | $54.47 | $69.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 20 |
| Target Price | $65.00 | ★ $106.85 |
| AVG Volume (30 Days) | 4.0M | ★ 10.6M |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ 55.20 |
| EPS | N/A | ★ 1.94 |
| Revenue | N/A | ★ $9,076,000,000.00 |
| Revenue This Year | N/A | $12.02 |
| Revenue Next Year | $3.92 | $10.41 |
| P/E Ratio | ★ $21.67 | $36.15 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $39.73 | $67.56 |
| 52 Week High | $55.11 | $109.50 |
| Indicator | ENB | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 37.82 |
| Support Level | $46.65 | $67.56 |
| Resistance Level | N/A | $71.94 |
| Average True Range (ATR) | 0.83 | 1.58 |
| MACD | -0.10 | 0.45 |
| Stochastic Oscillator | 73.56 | 38.93 |
Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.